References
Bell, J. The new genetics in clinical practice. British Medical Journal 1998;316:618–20
Anonymous. The new word in designer drugs. British Medical Journal 1998;316:1930
Chadwick, R. et al. When Drug Treatment in the Elderly is not cost-effective: An Ethical Dilemma in Environment of Healthcare Rationing. Drugs and Aging 1995;7(6):416–419
Chadwick, R. et al. (eds) (1997) The Right to Know and the Right not to Know. Aldershot: Avebury
Council on Ethical and Judicial Affairs, American Medical Association. Multiplex genetic testing, Hastings Center Report 1998;28(4):15–21
Danish Council of Ethics (1993) Ethics and Mapping of the Human Genome Copenhagen: Danish Council of Ethics
Hodgson, J. et al. Pharmacogenomics: will the regulators approve? Nature Biotechnology 1998;16:243–6
Housman, D. et al. Why pharmacogenomics? Why now? Nature Biotechnology 1998;16:492–3
Nuffield Council on Bioethics (1993) Genetic Screening: Ethical Issues London: Nuffield Council on Bioethics
Persidis, A. The business of pharmacogenomics. Nature Biotechnology 1998;16:209–10
Schmidt, K. Just for you. New Scientist 1998;160(2160):32–6
Stix, G. Personal pills. Scientific American 1998;279(4):10–11
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chadwick, R. Criteria for genetic screening: the impact of pharmaceutical research. Monash Bioethics Review 18, 22–26 (1999). https://doi.org/10.1007/BF03351215
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03351215